Recent advances in the chromatographic determination of the most commonly used anti‐hepatitis C drug sofosbuvir and its co‐administered drugs in human plasma

Abstract

Sofosbuvir is a direct‐acting antiviral drug that inhibits hepatitis C virus (HCV) NS5B polymerase, which in turn affects the virus replication inside biological systems. The clinical importance of sofosbuvir is based not only on its effect on HCV but also on other lethal viruses such as Zika and severe acute respiratory syndrome coronavirus disease 2019 (SARS‐COVID‐19). Accordingly, there is a continuous shedding of light on the development and validation of accurate and fast analytical methods for the determination of sofosbuvir in different environments. This work critically reviews the recent advances in chromatographic methods for the analysis of sofosbuvir and/or its metabolites in pure samples, pharmaceutical dosage forms, and in the presence of other co‐administered drugs to highlight the current status and future perspectives to enhance its determination in different matrixes.

Development and validation of LC–MS/MS methods for the simultaneous quantification of sofosbuvir and its major metabolite (GS‐331007) in blood plasma and cerebrospinal and seminal fluid: Application to a pilot clinical trial with a focus on Zika

“…Reversed‐phase C 8 and C 18 columns were tested, and the best performance was obtained with C 18 columns. According to a study review by Abdel‐Tawab et al (2022), most of the methods in the literature for the analysis of sofosbuvir and GS‐331007 in human plasma use C 18 columns as stationary phase.…”